Secretome Therapeutics

Secretome Therapeutics is a private, clinical-stage biotech founded in 2018 and headquartered in Cambridge, USA, with additional offices in Baltimore, Chicago, and Plano. The company's core innovation is a scalable platform using neonatal cardiac progenitor cells (nCPCs), which offer advantages in potency, manufacturing consistency, and ethical sourcing compared to adult-derived stem cells. It has two active Phase 1 clinical programs targeting DCM and HFpEF, positioning it in the competitive but high-need field of cell therapies for heart failure. The company is currently pre-revenue and focused on clinical development.

Platform for developing therapies from neonatal cardiac progenitor cells (nCPCs) and their secretome, emphasizing high potency, manufacturing consistency, and ethical sourcing from consented neonatal tissue.

Competes in the cell therapy for heart failure space against other biotechs and academic programs using adult stem cells (e.g., mesenchymal stem cells). Also faces broader competition from pharmaceutical companies developing novel pharmacologic treatments and gene therapies for heart failure and cardiomyopathies.